Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.6.1.25 (
triphosphatase
)
1,529
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The regulator of G-protein signaling (RGS) negatively regulates the alpha subunit of G proteins by accelerating their intrinsic guanosine
triphosphatase
(GTPase) activity. Here are reported the isolation and characterization of a novel mouse RGS, termed
RGS18
, which is a new member of RGS subfamily B. Northern blot analysis showed that
RGS18
messenger RNA was detected predominantly in spleen and hematopoietic cells, and immunohistochemical studies demonstrated that
RGS18
was expressed in megakaryocytes, platelets, granulocytes/monocytes, and, weakly, in hematopoietic stem cells, but not in lymphocytes or erythrocytes. Although various subcellular localizations of RGS have been reported,
RGS18
was found to be localized in cytoplasm in megakaryocytes. In vitro binding assays of
RGS18
with megakaryocyte cell lysates with or without AlF(4)(-) treatment demonstrated that
RGS18
specifically binds to 2 alpha subunits of the G protein, Galphai and Galphaq. Furthermore,
RGS18
clearly exhibited GTPase-activating protein (GAP) activity for Galphai and Galphaq but not for Galphas or Galpha12. In addition, chemokine stromal-derived factor 1 (SDF-1), which has been reported to stimulate megakaryocyte colony formation in the presence of thrombopoietin, affected the binding of
RGS18
to Galphai but not to Galphaq. Therefore, the newly isolated
RGS18
turned out to be a new member of the RGS family bearing GAP activity for Galphai, which might be stimulated by SDF-1 in megakaryocytes, as well as for Galphaq. Thus,
RGS18
may play an important role in proliferation, differentiation, and/or migration of megakaryocytes.
...
PMID:A novel regulator of G-protein signaling bearing GAP activity for Galphai and Galphaq in megakaryocytes. 1134 30